Evidence map›Paper›PMID 41542035›Full record

ArticleMolecular therapy. Oncology2026

MicroRNA-138 regulation promotes the efficacy of oncolytic herpes virus G47Δ for malignant brain tumor therapy.

Seisaku Kanayama, Takeshi Haraguchi, Hideo Iba, Minoru Tanaka, Tomoki Todo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Seisaku KanayamaDivision of Innovative Cancer Therapy and Department of Surgical Neuro-Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Takeshi HaraguchiDivision of RNA Therapy, Medical Mycology Research Center, Chiba University, Chiba, Japan.
Hideo IbaDivision of RNA Therapy, Medical Mycology Research Center, Chiba University, Chiba, Japan.
Minoru TanakaDivision of Innovative Cancer Therapy and Department of Surgical Neuro-Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Tomoki TodoDivision of Innovative Cancer Therapy and Department of Surgical Neuro-Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

G47Δ, a third-generation oncolytic herpes simplex virus type 1, is a promising therapeutic agent for malignant glioma. We investigated whether inhibition of host microRNA-138 (miR-138), a regulator of the viral immediate-early protein ICP0, could enhance its efficacy.

Indexed as

brain tumorsG47Δherpes simplex virus type 1malignant gliomamiR-138MT: Regular Issueoncolytic virus therapySTAT1

Identifiers

PMID41542035
PMCPMC12800491

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.